Table 4:
Univariate Logistic Regression for Patients Undergoing Bilateral Salpingo-oophorectomy (n=234) versus Ovarian Suppression (n=282) for Ovarian Ablation
| Variables | Levels | OR | 95%CI Lower Bounds | 95%CI Upper Bounds | p-value |
|---|---|---|---|---|---|
|
| |||||
| Age at Diagnosis | as 1 yr increase | 1.051 | 1.021 | 1.082 | <0.001 |
| Year of Diagnosis | 2011 vs 2010 | 1.075 | 0.589 | 1.960 | 0.082 |
| 2012 vs 2010 | 0.832 | 0.459 | 1.508 | ||
| 2013 vs 2010 | 0.581 | 0.329 | 1.025 | ||
| 2014 vs 2010 | 0.597 | 0.348 | 1.023 | ||
| Family History (15 unk.) | Yes vs No | 1.034 | 0.724 | 1.477 | 0.852 |
| Live Children | Yes vs No | 1.362 | 0.910 | 2.038 | 0.133 |
| Histology | 0.176 | ||||
| Lobular no ductal vs Ductal no lobular | 0.927 | 0.534 | 1.609 | ||
| Lobular and ductal vs Ductal no lobular | 2.522 | 1.192 | 5.334 | ||
| Inflammatory vs Ductal no lobular | 0.630 | 0.057 | 7.007 | ||
| Other vs Ductal no lobular | 0.841 | 0.139 | 5.083 | ||
| Grade (32 unk.) | G2 vs G1 | 0.639 | 0.210 | 1.941 | 0.286 |
| G3 vs G1 | 0.892 | 0.307 | 2.598 | ||
| LN Pos Exact (2 unk.) | Yes vs. No | 0.901 | 0.636 | 1.275 | 0.556 |
| Stage (59 unk.) | II vs. I | 1.130 | 0.745 | 1.713 | 0.777 |
| III vs. I | 0.962 | 0.590 | 1.568 | ||
| Chemotherapy | Yes vs. No | 1.179 | 0.806 | 1.727 | 0.396 |
| HER-2 Targeted | Trastuzumab vs. None | 1.587 | 0.902 | 2.790 | 0.076 |
| Trastuzumab+Other vs. None | 1.851 | 0.929 | 3.691 | ||
|
| |||||
The Odds Ratio (OR) is modeled for BSO yes, as OR>1 means more likely to get BSO, OR<1 less likely to get BSO. unk., unknown: number of patients in analysis who did not have documentation for this variable.
BSO, bilateral salpingo-oophorectomy; OS, ovarian suppression; LN, lymph node